Lamisilate (Terbinafine Hydrochloride)

Terbinafine hydrochloride blocks the fungal enzyme squalene epoxidase, preventing the synthesis of ergosterol, an essential component of fungal cell membranes. The resulting buildup of squalene and loss of ergosterol disrupts membrane integrity, leading to fungal cell death while sparing human cells.

The specific dosing regimen for Lamisilate is determined by the prescribing healthcare professional based on the infection type, severity, patient age and other clinical factors. Patients should follow the prescriber’s instructions and the product label for application frequency and duration.

Safety data for topical terbinafine during pregnancy or lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Lamisilate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamisilate (topical terbinafine) belongs to the allylamine class, offering a fungicidal mechanism that differs from azole or polyene antifungals. It often provides faster symptom relief and a lower risk of resistance for dermatophyte infections compared with some azole creams, but choice of therapy should be guided by the prescriber.

Lamisilate should be stored below 25 °C in its original container, protected from moisture and direct light. Keeping the product in a cool, dry place helps maintain its stability and effectiveness throughout its shelf life.

Lamisilate is applied topically to the affected skin area, usually once or twice daily as directed by the prescriber. The skin should be clean and dry before application, and the medication should be spread thinly to cover the lesion and a small margin of surrounding skin.

While rare, serious adverse reactions can include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, extensive blistering, or systemic hypersensitivity. Any signs of severe rash, swelling, or difficulty breathing require immediate medical attention.

Lamisilate should not be used by individuals with a known hypersensitivity to terbinafine, its salts, or any component of the formulation. It is also contraindicated on severely damaged or broken skin, and caution is advised in patients with a history of severe drug reactions.